Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2025-01-19 Regulatory Filings
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
US FDA Grants Rare Pediatric Disease Designation to VP-001 3 pages 248.4KB
Regulatory Filings Classification · 95% confidence The document is an announcement from PYC Therapeutics about the FDA granting Rare Pediatric Disease designation to their drug development program VP-001. It includes background information about the company, the drug programs, and forward-looking statements. There are no financial statements, quarterly or annual results, nor detailed management discussion of financial performance. The document is a regulatory announcement about a specific development related to drug designation by the FDA, not a financial report or earnings release. It is also not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about a significant company development that does not fit other categories.
2025-01-19 English
PYC Nominates Fourth Clinical Drug Candidate in PMS Program 4 pages 363.9KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from PYC Therapeutics about the nomination of a new clinical drug candidate (PYC-002) for Phelan-McDermid Syndrome. It includes scientific data from pre-clinical studies, descriptions of the drug's mechanism, and plans for future clinical trials. The content focuses on drug development progress and clinical pipeline updates rather than financial results, regulatory certifications, or shareholder meeting materials. It is not a financial report, audit, earnings release, or regulatory filing. The document is a corporate announcement about a clinical development milestone and future plans, which fits best under the category of a Capital/Financing Update (CAP) as it relates to the company's development pipeline and progression towards clinical trials, which is a form of capital/financing update relevant to investors and the market. The document length (over 10,000 characters) and detailed scientific data exclude it from being a simple announcement or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2024-12-15 English
Polycystic Kidney Disease Program Investor Presentation 12 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is a presentation dated November 2024 from PYC Therapeutics Limited, providing an update on the business and development progress of a drug candidate (PYC-003) for Polycystic Kidney Disease (PKD). It includes scientific data, clinical development plans, regulatory submission timelines, and potential FDA designations. The content is structured as a slide presentation with disclaimers, executive summary, scientific background, and Q&A. There is no indication that this is a formal regulatory filing, annual or interim financial report, earnings release, or legal document. The document is clearly a detailed presentation aimed at investors or stakeholders to update them on the company's strategy, science, and clinical development progress. Therefore, the most appropriate classification is Investor Presentation (IP).
2024-11-27 English
PYC to Progress Kidney Drug Candidate Into Human Trials 34 pages 2.8MB
Investor Presentation Classification · 95% confidence The document is a detailed announcement from a clinical-stage biotechnology company about the progression of a drug candidate (PYC-003) into human trials. It includes extensive pre-clinical study results, safety and efficacy data in animal models, pharmacokinetic studies, and plans for upcoming clinical trials. The document also mentions an investor webinar to present these results. There is no indication that this is a full annual or quarterly financial report, audit report, or earnings release. It is not a regulatory filing or certification, nor does it relate to governance, management changes, or legal proceedings. The content is focused on scientific and clinical development progress and investor communication. The presence of a webinar invitation and detailed presentation of clinical data aligns with an Investor Presentation (IP). The document length (15,000 characters) and detailed data support that this is a full presentation rather than a brief announcement or report publication notice.
2024-11-26 English
Change of Director's Interest Notice 2 pages 242.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in a director's relevant interests in securities, including shareholdings before and after a share consolidation. The document is a formal notification of a director's personal share transactions, specifically a reduction in holding due to a share consolidation. There is no financial performance data, earnings information, or management discussion. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3749 characters, consistent with a concise notice rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2024-11-26 English
Notification regarding unquoted securities - PYC 7 pages 20.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options under an employee incentive scheme by PYC Therapeutics Limited. It includes specifics such as the number of securities issued, exercise price, expiry date, and compliance with ASX listing rules. The content is a formal notification of a securities issue rather than a financial report or earnings release. This fits the category of a Share Issue/Capital Change announcement, as it reports on new securities issued and changes in capital structure.
2024-11-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.